Navigation Links
Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds
Date:3/15/2010

ST. LOUIS, March 15 /PRNewswire-FirstCall/ -- Sigma-Aldrich® (Nasdaq: SIAL) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications.

Under the agreement between the two companies, the Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time. The inclusion of these Pfizer compounds provides authentic material that will help advance researchers' understanding of biological systems.

"As part of our strategy to proactively seek the highest quality biologically rich products, it's exciting news for the life science research community that Pfizer is working with us to grant broad access to some of its most interesting and research-relevant bioactive small molecules," commented Dr. David Smoller, President of Sigma Life Science's Research Biotech Business Unit. "This multi-compound deal not only enriches our extensive portfolio of products with authentic Pfizer material but provides valuable resources that will enable our customers to modulate their protein targets, facilitating further advances in cellular and pathway biology."

"We are pleased to form this partnership with Sigma-Aldrich, a company with an excellent track record of respecting Pfizer's intellectual property.  Working with Sigma-Aldrich we are able to make authentic Pfizer compounds more readily available to the research community," added Rick Connell, Vice President and Worldwide Head of External Research Solutions Center of Excellence, Pfizer.

The Pfizer compounds will be sold worldwide directly through Sigma-Aldrich as in-stock, pre-packaged items and, upon request, in bulk, and will also be mapped to genes and associated pathways and interactors via Sigma-Aldrich's award-winning online search platform, 'Your Favorite Gene powered by Ingenuity' (http://www.sigma.com/yfg).  While the initial agreement includes approximately 100 Pfizer compounds, Sigma-Aldrich expects to add further Pfizer compounds on a regular basis.

The agreement with Pfizer represents the third such agreement Sigma-Aldrich has negotiated with a major pharmaceutical company.

For further information regarding this announcement, visit www.wherebiobegins.com/biomolecules.

Sigma-Aldrich Disclosure Notice: The foregoing release contains forward-looking statements that can be identified by terminology such as "far reaching and potential implications," "provides authentic material," "will help advance," "provides valuable resources," "enable our customers" or similar expressions, or by express or implied discussions regarding potential future revenues from products and services. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that these products will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biology and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,700 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

Sigma-Aldrich and Sigma are trademarks or registered trademarks of Sigma-Aldrich Biotechnology L.P. and Sigma-Aldrich Co.

SOURCE Sigma-Aldrich

Back to top

RELATED LINKS
http://www.sigma-aldrich.com

'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
2. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
3. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
4. Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.
5. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
6. Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend
7. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
8. Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
9. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
10. Save the Children Reaches More than 500,000 Children and Adults Two Months After Haiti Earthquake
11. MedCAREERS GROUP, Inc. Reaches Agreement in Principle to Acquire StaffMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology: